Recipient organisationNIHR Wellcome Trust Southampton Clinical Research Facility
NIHR supportRecorded as supported by this research centre
PeriodMay 2025 — Dec 2028
In plain English
AI plain-English summary
A new biologic drug, Tezepelumab, is helping some people with severe asthma achieve a state where their symptoms and flare-ups virtually disappear—and this study will track 350 patients across the UK and Europe for three years to find out why. Severe asthma affects roughly 5-10% of the 350 million people with asthma worldwide. Standard treatments often fail to control it, leaving patients with persistent inflammation, breathlessness, and frequent hospital visits. Tezepelumab blocks a protein called TSLP, which sits at the top of the inflammatory cascade, but it is not yet clear which patients are most likely to achieve remission—defined here as a combination of good symptom control, stable lung function, and no exacerbations—or what biological changes drive that improvement. If the researchers can identify the biomarkers and biological pathways linked to remission, clinicians could predict which patients will benefit most from Tezepelumab before starting treatment. This would allow more targeted prescribing, reduce trial-and-error, and potentially spare patients months of ineffective therapy. The findings could also guide the development of next-generation asthma drugs that aim for remission rather than just symptom management.
View original technical description
Asthma affects over 350 million people in the world. Approximately 5-10% of people with asthma have severe disease. Asthma is a lung disease associated with inflammation (swelling) of the airways. This study is a 36 month multicentre observational study of patients with severe asthma following initiation of treatment treatment with Tezepelumab (anti-TSLP) as part of their standard of care. Subjects will be extensively characterized at baseline; reviewed throughout the year with formal clinical and biological assessment at 4, 16, 52 weeks, 2 years and 3 years. Asthma remission will be defined for each domain: asthma control, lung function, and exacerbations as a composite measure and independently. Biomarkers and multi-omic analysis will be undertaken in the biosamples to determine biological pathways and bio-signatures associated with asthma remission. Primary outcome will be assessed at 1 year. In this research study we want to observe all participants having tezepelumab injections as part of their normal clinical care. We would like to try and understand what might be causing the high levels of disease control, including the absence of symptoms and exacerbations. By doing this we hope to be able to obtain informationthat may help to improve asthma treatment in the future. The study will be conducted at NHS hospitals throughout the UK and sites across Europe.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know